To interrogate if the combination treatment elicited systemic tumor-specific immunity, we examined spleens of the treated mice and found that there was indeed a significant increase in tetramer-positive CD8+ T cells (p < 0.001, Student’s T test; Fig. 5a, c). This evidence concerns the gene CD8A and neoplasm.